Phase 3 Positive preliminary ...
Phase 3 Positive preliminary be deriveds from a randomized Phase 3 trial demonstrated that the addition of carboplatin to Herceptin (trastuzumab) and paclitaxel deductioned in a six-month improvement in time to progression in make liables scored 3+ by immunohistochemistry (IHC), compared to the standard Herceptin and paclitaxel regimen. The subject of attention by Genentech (South San Francisco, CA) and Roche (Basel, Switzerland), evaluated the cogitation drug combination in first-line human epidermal increase factor receptor2 (HER2) positive metastatic breast cancer patients. The contemplation enrolled 194 women ...
|